ストックスクリーナーアプリを入手
84.89
2.81%
-2.45
アフターアワーズ：
84.89
前日終値:
$87.34
開ける：
$86.43
24時間の取引高:
2.51M
Relative Volume:
0.59
時価総額：
$33.29B
収益：
$4.15B
当期純損益:
$535.20M
株価収益率:
63.35
EPS:
1.34
ネットキャッシュフロー:
$575.20M
1週間 パフォーマンス:
-1.88%
1か月 パフォーマンス:
+28.41%
6か月 パフォーマンス:
+14.01%
1年 パフォーマンス:
-35.12%
1日の値動き範囲:
$84.50
$87.00
1週間の範囲:
$84.34
$87.65
52週間の値動き範囲:
$57.52
$131.76
Dexcom Inc Stock (DXCM) Company Profile
DXCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
84.89 | 33.93B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
133.05 | 223.67B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.64 | 152.31B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
379.75 | 147.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
84.41 | 108.05B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
76.10 | 45.02B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
Diabetic Care Device Market Set for Significant Growth with 10.1% CAGR - GlobeNewswire Inc.
3 Big Reasons to Love DexCom (DXCM) - Yahoo Finance
The End Of The Diabetes Industry?Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM) - Benzinga
FDA Approves DexCom G4 Platinum Professional Continuous Glucose Monitoring System - Medical Product Outsourcing
Can DexCom, Inc. (NASDAQ:DXCM) Maintain Its Strong Returns? - Yahoo Finance
Here's Why You Should Add DexCom Stock to Your Portfolio Now - MSN
Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products - MedTech Dive
Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount? - simplywall.st
Do Wall Street Analysts Like DexCom Stock? - Nasdaq
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook - Yahoo Finance
Dexcom Beats Investor Claims Over Sales Growth Potential for Now - Bloomberg Law News
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView
DexCom, Inc. (DXCM) Announces Leadership Promotion: Jacob S. Lea - GuruFocus
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO | DXCM Stock News - GuruFocus
DexCom (DXCM) Elevates Jake Leach to President - GuruFocus
Dexcom promotes Jake Leach to president role - MassDevice
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - Yahoo Finance
Dexcom Promotes Jake Leach to Expanded President, COO Role - Medical Product Outsourcing
DexCom Adds President Role to COO Jake Leach - marketscreener.com
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - Financial Times
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy - Yahoo Finance
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case - MSN
DXCM STOCK NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law about its Investigation if You Suffered Losses (DXCM) - ACCESS Newswire
Investor Network: DexCom, Inc. to Host Earnings Call - ACCESS Newswire
DexCom, Inc. (DXCM) Announces Key Approvals at Annual Meeting - GuruFocus
Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Dexcom Stockholders Approve Equity Plan Amendments - TipRanks
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure (NASDAQ:DXCM) - Seeking Alpha
Should You Investigate DexCom, Inc. (NASDAQ:DXCM) At US$85.34? - Yahoo Finance
Is DexCom, Inc. (DXCM) the Best Medical Device Stock to Buy Now? - Insider Monkey
Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - ACCESS Newswire
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Investors Who Lost Money on DexCom, Inc. (DXCM) Should Contact Levi & Korsinsky About Pending Class ActionDXCM - ACCESS Newswire
Investors who Lost Money on DexCom, Inc. (DXCM) Should Contact Levi & Korsinsky About Pending Class ActionDXCM - ACCESS Newswire
Lost Money on DexCom, Inc.(DXCM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
DXCM FRAUD UPDATE: DexCom, Inc. Investors are Encouraged to Contact BFA Law before the Expiration of the October 21 Legal Deadline in Securities Fraud Case - ACCESS Newswire
DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - ACCESS Newswire
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
3.16%
大文字化:
|
ボリューム (24 時間):